Cited by 1,506Atrial Fibrillation Management and OutcomesCardiac Valve Diseases and TreatmentsVenous Thromboembolism Diagnosis and Management

The DOI matches its Crossref record; 26 of the 27 references it cites were found in a registry or an index.

Dabigatran versus Warfarin in Patients with Mechanical Heart Valves

Eikelboom, John W., Connolly, Stuart J., Brueckmann, Martina, Granger, Christopher B., Kappetein, Arie P., Mack, Michael J., Blatchford, Jon, Devenny, Kevin, Friedman, Jeffrey, Guiver, Kelly, Harper, Ruth, Khder, Yasser, Lobmeyer, Maximilian T., Maas, Hugo, Voigt, Jens-Uwe, Simoons, Maarten L., Van de Werf, Frans·2013·New England Journal of Medicine

DOI 10.1056/nejmoa1300615

Open this paper in CoChat — free account

Abstract

BACKGROUND: Dabigatran is an oral direct thrombin inhibitor that has been shown to be an effective alternative to warfarin in patients with atrial fibrillation. We evaluated the use of dabigatran in patients with mechanical heart valves. METHODS: In this phase 2 dose-validation study, we studied two populations of patients: those who had undergone aortic- or mitral-valve replacement within the past 7 days and those who had undergone such replacement at least 3 months earlier. Patients were randomly assigned in a 2:1 ratio to receive either dabigatran or warfarin. The selection of the initial dabigatran dose (150, 220, or 300 mg twice daily) was based on kidney function. Doses were adjusted to obtain a trough plasma level of at least 50 ng per milliliter. The warfarin dose was adjusted to obtain an international normalized ratio of 2 to 3 or 2.5 to 3.5 on the basis of thromboembolic risk. The primary end point was the trough plasma level of dabigatran. RESULTS: The trial was terminated prematurely after the enrollment of 252 patients because of an excess of thromboembolic and bleeding events among patients in the dabigatran group. In the as-treated analysis, dose adjustment or discontinuation of dabigatran was required in 52 of 162 patients (32%). Ischemic or unspecified stroke occurred in 9 patients (5%) in the dabigatran group and in no patients in the warfarin group; major bleeding occurred in 7 patients (4%) and 2 patients (2%), respectively. All patients with major bleeding had pericardial bleeding. CONCLUSIONS: The use of dabigatran in patients with mechanical heart valves was associated with increased rates of thromboembolic and bleeding complications, as compared with warfarin, thus showing no benefit and an excess risk. (Funded by Boehringer Ingelheim; ClinicalTrials.gov numbers, NCT01452347 and NCT01505881.).

Integrity signals

Registry

Crossref · 10.1056/nejmoa1300615

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Dabigatran versus warfarin in patients with atrial fibrillation
Connolly, S. J., Ezekowitz, M. D., Yusuf, S., Eikelboom, J., Oldgren, J., Parekh, A., Pogue, J., Reilly, P. A., Themeles, E., Varrone, J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0905561 · Cited by 11,215
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation
Patel, M. R., Mahaffey, K. W., Garg, J., Pan, G., Singer, D. E., Hacke, W., Breithardt, G., Halperin, J. L., Hankey, G. J., Piccini, J. P., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009638 · Cited by 9,430
Apixaban versus warfarin in patients with atrial fibrillation
Granger, C. B., Alexander, J. H., McMurray, J. J. V., Lopes, R. D., Hylek, E. M., Hanna, M., Al-Khalidi, H. R., Ansell, J., Atar, D., Avezum, A., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107039 · Cited by 8,943
Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non‐surgical patients
Schulman, S., & Kearon, C. (2005) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2005.01204.x · Cited by 5,025
Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients
Schulman, S., Angerås, U., Bergqvist, D., ERIKSSON, B., Lassen, M. R., & FISHER, W. (2009) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2009.03678.x · Cited by 3,761
Guidelines on the management of valvular heart disease (version 2012)
Authors/Task Force Members, Vahanian, A., Alfieri, O., Andreotti, F., Antunes, M. J., Barón-Esquivias, G., Baumgartner, H., Borger, M. A., Carrel, T. P., De Bonis, M., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs109 · Cited by 3,559
A Method to Determine the Optimal Intensity of Oral Anticoagulant Therapy
Rosendaal, F. R., Cannegieter, S. C., van der Meer, F. J. M., & Briët, E. (1993) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1651587 · Cited by 2,070
Oral Anticoagulant Therapy
Ageno, W., Gallus, A. S., Wittkowsky, A. K., Crowther, M. A., Hylek, E. M., & Palareti, G. (2012) · CHEST Journal · doi:10.1378/chest.11-2292 · Cited by 1,583
Standardized endpoint definitions for transcatheter aortic valve implantation clinical trials: a consensus report from the Valve Academic Research Consortium
Leon, M. B., Piazza, N., Nikolsky, E., Blackstone, E. H., Cutlip, D. E., Kappetein, A. P., Krucoff, M. W., Mack, M. J., Mehran, R., Miller, D. C., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehq406 · Cited by 1,217
Mechanisms of thrombogenesis in atrial fibrillation: Virchow's triad revisited
Watson, T., Shantsila, E., & Lip, G. Y. H. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60040-4 · Cited by 1,124

Flagged first, then by citations

Show all 27 references

1 of the 27 references couldn’t be matched to a known paper.

Research works printed but not linked: 1

Dewanjee MK, 1999, J Heart Valve Dis, 8, 324

Sorted by citations

Items 701–800 of 1,000

Safety and Efficacy of Non–Vitamin K Oral Anticoagulant Use Early After Cardiac Surgery: A Systematic Review
Wang, E. H. Z., Ye, J., & Turgeon, R. D. (2021) · Annals of Pharmacotherapy · doi:10.1177/10600280211006830 · Cited by 7
Analysis of the ESC/EACTS 2020 Atrial Fibrillation Guidelines With Perioperative Implications
Nelson, J. A., Gue, Y. X., Christensen, J. M., Lip, G. Y. H., & Ramakrishna, H. (2021) · Journal of Cardiothoracic and Vascular Anesthesia · doi:10.1053/j.jvca.2021.05.011 · Cited by 8
Comparison of the Direct Oral Anticoagulants and Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: Updated Systematic Review and Meta-Analysis of Randomized Controlled Trials
Bitar, Y. D. S. L., Durães, A. R., Roever, L., Neto, M. G., Lins-Kusterer, L., & Bocchi, E. A. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.712585 · Cited by 8
“(14), events in stroke/major bleeding/intracranial”
BackgroundMethod
Direct Oral Anticoagulants: Overcoming the Challenges of Managing Venous Thromboembolism in Children
Male, C., Monagle, P., Albisetti, M., Brandão, L. R., & Young, G. A. (2021) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2021.09.025 · Cited by 7
Dabigatran in cardiovascular disease management: A comprehensive review
Javed, A., Ajmal, M., & Wolfson, A. (2021) · World Journal of Cardiology · doi:10.4330/wjc.v13.i12.710 · Cited by 7
Advances in anticoagulation: patients with bioprosthetic heart valves
Carlin, S., & Eikelboom, J. W. (2021) · Cardiovascular Research · doi:10.1093/cvr/cvab360 · Cited by 7
Effectiveness and safety of non-vitamin K direct oral anticoagulants in atrial fibrillation patients with bioprosthetic valve
Moon, I., Go, T., Kim, J., Kang, D. R., Sohn, S. H., Lee, H., Choi, J. W., Park, J., Hwang, H.-Y., Kim, H., et al. (2022) · PLoS ONE · doi:10.1371/journal.pone.0268113 · Cited by 7
“In those with mechanical heart valves, dabigatran has also been shown to be inferior to warfarin [23].”
Background
An Updated Meta-Analysis of DOACs vs. VKAs in Atrial Fibrillation Patients With Bioprosthetic Heart Valve
Cao, Y., Zheng, Y., Li, S., Liu, F., Xue, Z., Yin, K., & Luo, J. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.899906 · Cited by 8
“However, when it comes to patients with bioprosthetic heart valves (BPHV), the use of DOACs is contraindicated to a large extent, and warfarin is the only permitted oral anticoagulant (4).”
BackgroundMethod
The Efficacy and Safety of Direct Oral Anticoagulants for The Treatment of Venous Thrombosis in Cancer Using Fuzzy PROMETHEE
Ozsahin, D. U., Usanase, N., Ozsahin, D. U., Özşahin, İ., & Balcıoğlu, Ö. (2023) · Advances in Science and Engineering Technology International Conferences (ASET) · doi:10.1109/aset56582.2023.10180505 · Cited by 7
Direct Oral Anticoagulants: An Overview of Indications, Pharmacokinetics, Comorbidities, and Perioperative Management
Moras, E., Gandhi, K., Khan, M., Moras, A., Choi, J., Frishman, W. H., & Aronow, W. S. (2023) · Cardiology in Review · doi:10.1097/crd.0000000000000618 · Cited by 8
Sailing between scylla and charybdis—anticoagulation dilemma in a patient with calciphylaxis and mechanical cardiac valve replacement: a case report and literature review
Liang, S., Guan, M., Liu, Z., Ruan, X., Huang, H., & Zhong, H. (2023) · Renal Failure · doi:10.1080/0886022x.2023.2264401 · Cited by 8
Selecting antithrombotic therapy for patients with atrial fibrillation
Tanaka‐Esposito, C., & Chung, M. K. (2014) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.82a.140002 · Cited by 8
Role of Novel Anticoagulants for Patients with Mechanical Heart Valves
Forsberg, P. A., & DeSancho, M. T. (2014) · Current Atherosclerosis Reports · doi:10.1007/s11883-014-0448-7 · Cited by 7
Oral Anticoagulation in the Elderly: New Oral Anticoagulants–Innovative Solution for an Old Problem?
Barbosa, M., & Falcão, L. M. (2016) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000000452 · Cited by 7
Dabigatran etexilate in a vitamin-K antagonist non responder patient during Heartware HVAD support
Baronetto, A., Centofanti, P., Attisani, M., Boffini, M., Ricci, D., Simonato, E., & Rinaldi, M. (2017) · Journal of Cardiac Surgery · doi:10.1111/jocs.13097 · Cited by 7
A Case with Recurrent Free-Floating Ball Thrombi in Left Atrium
Yoshioka, T., Mori, T., Taniguchi, Y., Hirayama, S., Ozawa, T., Iwata, S., Takei, A., & Inoue, N. (2017) · American Journal of Case Reports · doi:10.12659/ajcr.902633 · Cited by 7
Orale Antikoagulation mit Vitamin K-Antagonisten – ein Update
Sucker, C., & Litmathe, J. (2017) · Wiener Medizinische Wochenschrift · doi:10.1007/s10354-017-0577-z · Cited by 7
Anticoagulation after coronary stenting: a systemic review
Dong, Z., & Zheng, J. (2017) · British Medical Bulletin · doi:10.1093/bmb/ldx018 · Cited by 7
A Narrative Review for Perioperative Physicians of the 2017 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants
Fabbro, M., Dunn, S. A., Rodriguez‐Blanco, Y. F., & Jain, P. (2018) · Journal of Cardiothoracic and Vascular Anesthesia · doi:10.1053/j.jvca.2018.07.023 · Cited by 7
Venous Thromboembolism: A Survey of Oral Anticoagulant Preferences in the Treatment of Challenging Patient Populations
Moyer, G. C., Bannow, B. S., Thornburg, C. D., Rosovsky, R. P. G., Wang, T., Woller, S. C., Thornhill, D., & Kreuziger, L. B. (2018) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/1076029618804080 · Cited by 7
“This likely reflects a paucity of evidence and increased caution around use of DOACs in patients perceived to be highly hypercoagulable.(22,23) A number of ongoing trials seek to study the efficacy of DOACs such as rivaroxaban and apixaban in patients with APS.”
Background
Periprocedural Anticoagulation Management For Nonoperating Room Anesthesia Procedures: A Clinical Guide
Tao, J. Z., & Oprea, A. D. (2019) · Seminars in Cardiothoracic and Vascular Anesthesia · doi:10.1177/1089253219870627 · Cited by 7
The Effect of Warfarin Administration Time on Anticoagulation Stability (INRange): A Pragmatic Randomized Controlled Trial
Garrison, S., Green, L. A., Kolber, M. R., Korownyk, C. S., Olivier, N., Heran, B. S., Flesher, M. E., & Allan, G. M. (2020) · The Annals of Family Medicine · doi:10.1370/afm.2488 · Cited by 7
Effect of rifampicin on anticoagulation of warfarin: A case report
Hu, Y.-N., Zhou, B., Yang, H., Peng, Q., Gu, X., & Sun, S. (2021) · World Journal of Clinical Cases · doi:10.12998/wjcc.v9.i5.1087 · Cited by 7
Self-management of warfarin therapy
Sølvik, U. Ø., Løkkebø, E. S., Kristoffersen, A. H., Stavelin, A. V., Binder, S., & Sandberg, S. (2015) · Tidsskrift for Den norske legeforening · doi:10.4045/tidsskr.14.0768 · Cited by 7
Real-World Anticoagulatory Treatment After Transcatheter Aortic Valve Replacement: A Retrospective, Observational Study on 4,800 Patients
Hohmann, C., Ludwig, M., Walker, J., Wienemann, H., Baldus, S. E., & Pfister, R. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.780762 · Cited by 7
Home management of INR in the public health system: feasibility of self-management of oral anticoagulation and long-term performance of individual POC devices in determining INR
Saraiva, S. D. S., Orsi, F. A., dos Santos, M. P., Machado, T. F. G. S., Montalvão, S. A. D. L., Costa-Lima, C., Paula, E. V. D., Colella, M. P., & Annichino‐Bizzacchi, J. M. (2016) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-016-1335-6 · Cited by 7
Heart Disease in Pregnancy
Coulter, S., Lew, J., & Jenny, B. E. (2019) · Cardiovascular medicine · doi:10.1007/978-1-4471-2840-3_12 · Cited by 5
Non-vitamin K oral anticoagulants in adults with congenital heart disease: quod non?
Verhamme, P. B., Budts, W., & de Werf, F. V. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa867 · Cited by 7
ANMCO Position Paper: direct oral anticoagulants for stroke prevention in atrial fibrillation: clinical scenarios and future perspectives
Nardi, F., Gulizia, M. M., Colivicchi, F., Abrignani, M. G., Fusco, S. A. D., Lenarda, A. D., Tano, G. D., Geraci, G., Moschini, L., Riccio, C., et al. (2017) · European Heart Journal Supplements · doi:10.1093/eurheartj/sux007 · Cited by 6
Safety and Efficacy of Apixaban Following Bioprosthetic Valve Replacements: A Retrospective Evaluation
Ball, K., & Covington, E. W. (2021) · Journal of Pharmacy Technology · doi:10.1177/87551225211021596 · Cited by 6
Living on Oral Anticoagulants: Duke Anticoagulation Satisfaction Scale Results
Mameli, A., Sestu, A., Marongiu, F., & Barcellona, D. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12247574 · Cited by 7
“…mitral stenosis [10,11], antiphospholipid syndrome [12], severe renal failure with a glomerular ﬁltration rate 30 mL/min for direct thrombin inhibitor and 15 mL/min for anti-Xa inhibitors [10], cirrhotic patients with a Child-Pugh score of B or C [10], mechanical prosthetic heart valves [13].”
Background
Chinese Guidelines for the Diagnosis and Management of Atrial Fibrillation
Chinese Society of Cardiology, C. M. A., & Heart Rhythm Committee of Chinese Society of Biomedical Engineering (2024) · Cardiology Discovery · doi:10.1097/cd9.0000000000000123 · Cited by 7
Low incidence of thromboembolism with Fiix-monitored warfarin compared to conventional warfarin and DOACs in patients with AF
Ingason, A. B., Guðmundsdóttir, B. R., Pálsson, R., Hreinsson, J. P., Lund, S. H., Letertre, L. R., Rumba, E., Agustsson, A. S., Bjornsson, E. S., & Onundarson, P. T. (2025) · Blood Vessels Thrombosis & Hemostasis · doi:10.1016/j.bvth.2025.100056 · Cited by 6
Efficacy and safety of apixaban versus vitamin K antagonists in patients with heartmate 3 fully magnetically levitated left ventricular assist device: a comprehensive meta-analysis
Tripoli, A., Samaniego-Laguna, M. A., Valverde, N. N. G., Selvam, S., Kaplinsky, E., Barbagelata, A., Scandroglio, A. M., & Giorgi, J. M. (2025) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-025-03141-y · Cited by 6
Emergency department management of patients on novel oral anticoagulant agents.
Raja, A. S., & Geyer, B. C. (2013) · PubMed · Cited by 6
Anticoagulation Considerations for Travel to High Altitude
DeLoughery, T. G. (2015) · High Altitude Medicine & Biology · doi:10.1089/ham.2015.0058 · Cited by 6
“The direct oral anticoagulants are contraindicated because the only study of their use in valves showed excess rates of bleeding and thrombosis (Eikelboom et al., 2013).”
Restarting oral anticoagulants after intracerebral hemorrhage: pros
Ntaios, G. (2014) · Internal and Emergency Medicine · doi:10.1007/s11739-014-1160-x · Cited by 6
“Unfortunately, one should keep in mind that this is the case for patients with AF or VTE, but not for patients with mechanical heart valves, for whom dabigatran was recently shown to be associated with worse outcome compared to warfarin [20].”
Result
Update for 2014 on Clinical Cardiology, Geriatric Cardiology, and Heart Failure and Transplantation
Barón‐Esquivias, G., Manito, N., López, J., Santana, A. M., Pinilla, J. M. G., Gómez‐Doblas, J. J., Gómez-Bueno, M. F., Alonso, V. B., & Lambert, J. L. (2015) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2014.12.008 · Cited by 6
Actualización 2014 en cardiología clínica, cardiología geriátrica e insuficiencia cardiaca y trasplante
Barón‐Esquivias, G., Manito, N., Díaz, J. L., Santana, A. M., Pinilla, J. M. G., Gómez‐Doblas, J. J., Gómez-Bueno, M. F., Barrios, V., & Lambert, J. L. (2015) · Revista Española de Cardiología · doi:10.1016/j.recesp.2014.12.009 · Cited by 6
Non-vitamin K antagonist oral anticoagulants in patients with an increased risk of bleeding
Gremmel, T., Niessner, A., Domanovits, H., Frossard, M., Sengölge, G., Steinlechner, B., Sycha, T., Wolzt, M., & Pabinger, I. (2018) · Wiener klinische Wochenschrift · doi:10.1007/s00508-018-1381-5 · Cited by 5
Pharmacogenetic-guided and clinical warfarin dosing algorithm assessments with bleeding outcomes risk-stratified by genetic and covariate subgroups
Dietz, N., Ruff, C. T., Giugliano, R. P., Mercuri, M. F., & Antman, E. M. (2020) · International Journal of Cardiology · doi:10.1016/j.ijcard.2020.03.055 · Cited by 6
Direct Oral Anticoagulants After Percutaneous Patent Foramen Ovale (PFO) Closure: A Call for Caution
Bovin, A., Vase, H. Ø., Nielsen‐Kudsk, J. E., & Grove, E. L. (2020) · American Journal of Case Reports · doi:10.12659/ajcr.922467 · Cited by 6
Warfarin sensitivity is associated with increased hospital mortality in critically Ill patients
Ma, Z., Wang, P., Mahesh, M., Elmi, C. P., Atashpanjeh, S., Khalighi, B., Cheng, G., Krishnamurthy, M., & Khalighi, K. (2022) · PLoS ONE · doi:10.1371/journal.pone.0267966 · Cited by 6
“The RE-ALIGN trial for the use of dabigatran versus warfarin in patients with mechanical heart valves was also terminated prematurely due to an excess of both thromboembolic events and bleeding events among patients in the dabigatran group [22].”
Background
Anticoagulants: dose control methods and inhibitors
Bitsadze, V. O., Викторовна, С. Е., Khizroeva, J. K., Tretyakova, M. V., Tsibizova, V. I., Gashimova, N. R., Nakaidze, I. A., Elalamy, I., Gris, J., & Makatsariya, A. D. (2022) · Obstetrics Gynecology and Reproduction · doi:10.17749/2313-7347/ob.gyn.rep.2022.293 · Cited by 6
Thrombotic Antiphospholipid Syndrome and Direct Oral Anticoagulants: Unmet Needs and Review of the Literature
Marco, A., & Marco, P. (2023) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0043-1767728 · Cited by 7
Efficacy and Safety of Novel Oral Anticoagulants in Atrial Fibrillation: A Systematic Review
Roy, P. B., Tejani, V. N., Dhillon, S. S., Damarlapally, N., Winson, T., Usman, N. U. B., & Panjiyar, B. K. (2023) · Cureus · doi:10.7759/cureus.46385 · Cited by 6
“…and safety of dabigatran have been proven to be inferior to warfarin in patients with mechanical heart valves in the report of the RE-ALIGN (Randomized Phase II Study to Evaluate the Safety and Pharmacokinetics of Oral Dabigatran Etexilate in Patients after Heart Valve Replacement) trial [26].”
Background
Selection of Non-vitamin K Antagonist Oral Anticoagulant for Stroke Prevention in Atrial Fibrillation Based on Patient Profile: Perspectives from Vietnamese Experts. Part 1
Ho, T. H. Q., Ton, M. T., Nguyen, V. L., Pham, H. M., Hoang, S. V., Vo, N. T., Nguyen, T. Q., Pham, L. T., Mai, T. D., & Nguyen, T. H. (2023) · European Cardiology Review · doi:10.15420/ecr.2023.24 · Cited by 6
“16,17 Certain populations, including patients with thrombocytopenia, end-stage renal disease and those undergoing dialysis, were intentionally excluded from pivotal trials.”
Background
Risk of Stroke and Death in Atrial Fibrillation by Type of Anticoagulation: A Propensity-Matched Analysis
Leef, G. C., Qin, D., Althouse, A. D., Alam, M. B., RATTAN, R., Munir, M. B., Patel, D. R., Khattak, F. H., Vaghasia, N., ADELSTEIN, E. C., et al. (2015) · Pacing and Clinical Electrophysiology · doi:10.1111/pace.12695 · Cited by 6
The place of new oral anticoagulants in travel medicine
Ringwald, J., Grauer, M., Eckstein, R., & Jelínek, T. (2013) · Travel Medicine and Infectious Disease · doi:10.1016/j.tmaid.2013.11.005 · Cited by 6
The Current and Future Role of the Novel Oral Anticoagulants—Indications Beyond Atrial Fibrillation
Lee, A., & Rajaratnam, R. (2013) · Heart Lung and Circulation · doi:10.1016/j.hlc.2013.09.007 · Cited by 6
Indications and appropriate selection of novel oral anticoagulants in patients with atrial fibrillation
Ghannam, M., & Chugh, A. (2017) · Heart · doi:10.1136/heartjnl-2014-307030 · Cited by 6
A Comprehensive Appraisal of Dabigatran Etexilate Clinical Evidence and Applications: A 10-year-long Story
Romiti, G. F., Corica, B., & Proietti, M. (2020) · Future Cardiology · doi:10.2217/fca-2020-0084 · Cited by 6
Bioprosthetic valves and atrial fibrillation: Direct anticoagulants or warfarin
Kapadia, S. R., & Svensson, L. G. (2021) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2021.05.051 · Cited by 6
Direct-acting oral anticoagulants versus warfarin in relation to risk of gastrointestinal bleeding: a systematic review and meta-analysis of randomized controlled trials
Aloysius, M. M. (2021) · Annals of Gastroenterology · doi:10.20524/aog.2021.0658 · Cited by 7
Risk of device-related thrombosis following short-term oral anticoagulation with low-dose dabigatran versus warfarin after Watchman left atrial appendage occlusion
Ge, H., Zhang, C., Qiao, Z., Hao, Z., Li, Z., Gu, Z., Jiang, L.-S., He, B., & Pu, J. (2022) · Science Progress · doi:10.1177/00368504221113194 · Cited by 6
Assessment and Reporting of Harm
Friedman, L. M., Furberg, C. D., DeMets, D. L., Reboussin, D. M., Granger, C. B., & Moore, T. J. (2015) · Springer eBooks · doi:10.1007/978-3-319-18539-2_12 · Cited by 6
Difficult situations in anticoagulation after stroke
Ntaios, G., & Lip, G. Y. H. (2015) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000283 · Cited by 6
Fibrilación auricular: enfoque para el médico no cardiólogo
de Caldas, U., Forero, J., Moreno, J., del Bosque, U., Agudelo, C. A., Cayre, I. P. S., Rodríguez, E., de Manizales, I. D. C., & Sánchez, P. (2017) · IATREIA · doi:10.17533/udea.iatreia.v30n4a05 · Cited by 7
“IATREIA Vol 30(4) octubre-diciembre 2017 415 eficacia de dabigatran para prevenir ECV en pacientes con prótesis valvulares mecánicas (89) hace que no se pueda recomendar su uso en este grupo de pacientes hasta no contar con ensayos clínicos que los evalúen en este contexto (89), siendo rivaroxaban y edoxaban las alter…”
Background
Introduction and general comments
Iung, B., & Kappetein, A. P. (2018) · doi:10.1093/med/9780198784906.003.0764 · Cited by 6
Mechanical Prosthetic Heart Valve Thrombosis in a Patient Receiving Rivaroxaban
Silva, D. M. C., Braga, A., de Jesus, I., & Neves, J. K. (2019) · Cardiology · doi:10.1159/000501361 · Cited by 6
Choosing the best antithrombotic regimen in patients with ventricular assist devices
Bader, F. M., Mallah, S. I., & Atallah, B. (2019) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000708 · Cited by 6
“Although dabigatran was comparable with VKA in another small retrospective study with HMII patients and had less major bleeding [23], it has also previously failed with a mechanical valve population showing increased risk of thromboembolic and bleeding complications when compared with warfarin [24].”
Result
Antithrombotic therapy for stroke prevention in patients with atrial fibrillation in Japan
Maruhashi, T., & Higashi, Y. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2020.1799976 · Cited by 7
Meta-analysis of Direct Oral Anticoagulants in Patients With Atrial Fibrillation and Bioprosthetic Valves
Kheiri, B., Przybylowicz, R., Simpson, T. F., Alhamoud, H., Osman, M., Dalouk, K. A., Nazer, B., Henrikson, C. A., & Stecker, E. C. (2020) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2020.12.006 · Cited by 6
Non-vitamin K oral anticoagulants in ‘valvular’ atrial fibrillation: a call for action
Steffel, J., & Atar, D. (2015) · EP Europace · doi:10.1093/europace/euv318 · Cited by 6
Tecarfarin: A Novel Vitamin K Antagonist
Hobl, E., & Jilma, B. (2017) · Thrombosis and Haemostasis · doi:10.1160/th17-08-0594 · Cited by 6
AI‐assisted warfarin dose optimisation with CURATE . AI for clinical impact: Retrospective data analysis
Gan, T. R. X., Tan, L. W. J., Egermark, M., Truong, A. T. L., Kumar, K. S., Tan, S., Tang, S. S. L., Blasiak, A., Goh, B. C., Ngiam, K. Y., et al. (2025) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10757 · Cited by 5
Antithrombotic Therapy in People with Hemophilia—A Narrative Review
Nagao, A., Goto, S., & Goto, S. (2025) · Thrombosis and Haemostasis · doi:10.1055/a-2548-4192 · Cited by 5
The Use of Direct Oral Anticoagulants (DOACs) in the Geriatric Population—How to Overcome the Challenges of Geriatric Syndromes
Bădescu, M. C., Popescu, D., Gosav, E. M., Costache, A. D., Cosău, D. E., Chetran, A., Duca, Ș.-T., Cucută, S., Șerban, I. L., Enache, I. I. C., et al. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14134396 · Cited by 5
“…valves with or without AF, those with AF and concomitant moderate-to-severe mitral valve stenosis, and patients with thrombotic antiphospholipid syndrome are not eligible for a DOAC because, in these settings, DOACs showed inferiority to VKAs in protection against thromboembolic events [98–100].”
Comparative Outcomes of Apixaban and Acenocoumarol in Advanced Chronic Kidney Disease and Atrial Fibrillation: A Retrospective Observational Study
Suliman, I. L., Tuta, L. A., Panculescu, F. G., Alexandru, A., Fasie, D., Cîmpineanu, B., Cozaru, G. C., Popescu, S., Enache, F.-D., Manac, I., et al. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14248860 · Cited by 5
“Similar outcomes have been documented in large-scale studies demonstrating reduced bleeding and comparable stroke prevention with apixaban versus warfarin across CKD stages [26,27].”
2025 ESC/EACTS Guidelines for the management of valvular heart disease
Praz, F., Borger, M. A., Lanz, J., Cuartas, M. M., Abreu, A., Adamo, M., Marsan, N. A., Barili, F., Bonaros, N. E., Cosyns, B., et al. (2025) · European Heart Journal - Valvular and Structural Heart Disease · doi:10.1093/ehjvshd/xwag001 · Cited by 6
VAD therapy 20/20: moving beyond the myopic view of a nascent therapy.
DeVore, A. D., Milano, C. A., & Rogers, J. G. (2014) · PubMed Central · doi:10.3978/j.issn.2225-319x.2014.08.22 · Cited by 5
“com for stroke prevention in patients with non-valvular atrial fibrillation have improved safety and efficacy compared to warfarin (3), but their use is currently limited in more high-risk settings such as mechanical heart valves (4).”
Background
Almanac 2014: aortic valve disease
Otto, C. M. (2015) · Heart · doi:10.1136/heartjnl-2014-306027 · Cited by 5
Monitoring anti-factor Xa activity in patients with chronic thromboembolic pulmonary hypertension treated with factor Xa inhibitors
Nakano, Y., Adachi, S., Hirose, M., Adachi, T., Nishiyama, I., Yasuda, K., Yoshida, M., Kondo, T., & Murohara, T. (2024) · Scientific Reports · doi:10.1038/s41598-024-74481-7 · Cited by 5
Anticoagulants: From chance discovery to structure-based design
Chan, N., Carlin, S., & Hirsh, J. (2025) · Pharmacological Reviews · doi:10.1016/j.pharmr.2025.100037 · Cited by 7
Periprocedural Management of Patients on Anticoagulants
Williams, L. A., Hunter, J. M., Marques, M. B., & Vetter, T. R. (2014) · Clinics in Laboratory Medicine · doi:10.1016/j.cll.2014.06.010 · Cited by 5
Thrombo-embolic events in left ventricular endocardial pacing: long-term outcomes from a multicentre UK registry
Sawhney, V., Domenichini, G., Gamble, J. H. P., Furniss, G., Panagopoulos, D., Lambiase, P. D., Rajappan, K., CHOW, A. W. C., LOWE, M. D., Sporton, S. C., et al. (2018) · EP Europace · doi:10.1093/europace/euy107 · Cited by 5
Oral anticoagulant use in cardiovascular disorders: a perspective on present and potential indications for rivaroxaban
Camm, A. J., & Fox, K. A. A. (2018) · Current Medical Research and Opinion · doi:10.1080/03007995.2018.1467885 · Cited by 5
Animal Assisted Interactions to Alleviate Psychological Symptoms in Patients on Mechanical Ventilation.
Hetland, B. D., Bailey, T., & Prince‐Paul, M. (2017) · PubMed · Cited by 5
Alternatives for Vitamin K Antagonists as Thromboprophylaxis for Mechanical Heart Valves and Mechanical Circulatory Support Devices: A Systematic Review
Liesdek, O. C. D., Urbanus, R. T., de Heer, L. M., Fischer, K., Suyker, W. J. L., & Schutgens, R. E. G. (2021) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0041-1722846 · Cited by 5
Factor Xa Inhibitors for Patients after Mechanical Heart Valve Replacement?
Gerfer, S., Grandoch, M., Wahlers, T., & Kuhn, E. W. (2021) · The Thoracic and Cardiovascular Surgeon · doi:10.1055/s-0041-1736242 · Cited by 5
Antithrombotika und Antihämorrhagika
Hein, L., & Wille, H. (2016) · Springer eBooks · doi:10.1007/978-3-662-50351-5_18 · Cited by 5
Transcatheter Versus Surgical Aortic Valve Replacement in Young, Low-risk Patients with Severe Aortic Stenosis
Nguyen, Q., Luc, J. G. Y., MacGillivray, T. E., & Preventza, O. A. (2022) · US Cardiology Review · doi:10.15420/usc.2022.08 · Cited by 5
Comparison of Direct Oral Anticoagulants and Warfarin in the Prevention of Stroke in Patients With Valvular Heart Disease: A Meta-Analysis
Batool, S. A., Chaudhari, S. S., Shaik, T. A., Dhakal, S., Ganaie, Z. A., Ghaffari, M. A. Z., Saleem, F., & Khan, A. A. (2022) · Cureus · doi:10.7759/cureus.28763 · Cited by 5
“Overall, five studies involving 8916 patients with VHD compared all-cause mortality between the two groups [11-15].”
BackgroundInfluential
Effects of Direct Oral Anticoagulants’ Nonrecommended Dose in Atrial Fibrillation: A Meta-Analysis
Mosconi, M. G., Maraziti, G., Paciaroni, M., Giustozzi, M., Vedovati, M. C., Bogliari, G., Urbini, C., Traballi, L., & Caso, V. (2022) · European Neurology · doi:10.1159/000525407 · Cited by 5
Impact of type of oral anticoagulants in patients with cerebral microbleeds after atrial fibrillation-related ischemic stroke or TIA: Results of the NOACISP-LONGTERM registry
Wagner, B., Hert, L., Polymeris, A. A., Schaedelin, S. A., Lieb, J. M., Seiffge, D. J., Traenka, C., Thilemann, S., Fladt, J. C., Altersberger, V. L., et al. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2022.964723 · Cited by 5
Why Does Rivaroxaban Not Work in Severe Mitral Stenosis?
Marongiu, F., & Barcellona, D. (2023) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0043-1768938 · Cited by 5
Analysis of The 2024 ESC/EACTS Guidelines For The Management Of Atrial Fibrillation
Ripoll, J. G., Chang, M. G., Bittner, E. A., Ortoleva, J. P., Khromava, M., Bradley, D. T., Griffin, E. K., Soto, J. C. D., Wieruszewski, P. M., Chang, K., et al. (2024) · Journal of Cardiothoracic and Vascular Anesthesia · doi:10.1053/j.jvca.2024.11.020 · Cited by 8
Left atrial appendage closure in a patient with atrial fibrillation after mechanical mitral valve replacement and cardio-embolic stroke despite effective oral anticoagulant therapy: a case report
Sedaghat, A., Nickenig, G., & Hammerstingl, C. (2014) · Clinical Research in Cardiology · doi:10.1007/s00392-014-0704-4 · Cited by 5
“However, recent data concerning increased thromboembolic complications with the use of dabigatran in patients with mechanical heart valves [7] and lack of scientific data for other direct acting OAC (rivaroxaban, apixaban) in these patients led to the decision for percutaneous LAAc to achieve mechanical obliteration o…”
Background
Dabigatran Versus Warfarin After Bioprosthesis Valve Replacement for the Management of Atrial Fibrillation Postoperatively: Protocol
Durães, A. R., Roriz, P. D. S., de Bulhões, F. V., Nunes, B. D. A., Muniz, J. Q. V., Neto, I. N., Fernandes, A. M. S., dos Reis, F. J. F. B., Câmara, E. J. N., Erenaldo, D. S. R., et al. (2014) · JMIR Research Protocols · doi:10.2196/resprot.3014 · Cited by 5
Neurologic complications of valvular heart disease
Cruz‐Flores, S. (2013) · Handbook of clinical neurology · doi:10.1016/b978-0-7020-4086-3.00006-0 · Cited by 5
Theme 3: Non-invasive management of (recurrent) venous thromboembolism (VTE) and post thrombotic syndrome (PTS)
ten Cate‐Hoek, A. J., Weitz, J. I., Gailani, D., Meijer, K., Philippou, H., Bouman, A. C., Cheung, Y. W., van Mens, T. E., Govers‐Riemslag, J. W. P., Vries, M. J. A., et al. (2015) · Thrombosis Research · doi:10.1016/j.thromres.2015.07.036 · Cited by 5
Direct Oral Anticoagulants in Dental Patients Including the Frail Elderly Population
Lim, H. Y., & Ho, P. W. (2016) · Dentistry Journal · doi:10.3390/dj4010007 · Cited by 5
Horseshoe thrombus in a patient with mechanical prosthetic mitral valve: A case report and review of literature
Mehra, S. (2015) · World Journal of Clinical Cases · doi:10.12998/wjcc.v3.i9.838 · Cited by 5
Vitamin K Antagonists (Coumarins), Drugs Used in the Prevention and Treatment of Cardioembolism, Deep Vein Thrombosis, and Pulmonary Embolism
Marongiu, F., & Barcellona, D. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-411462-3.00040-0 · Cited by 5
Evolving cardiovascular uses of direct-acting oral anticoagulants: a paradigm shift on the horizon?
Raschi, E., Bianchin, M., Fantoni, C., Ageno, W., Ponti, F. D., & Ponti, R. D. (2017) · Internal and Emergency Medicine · doi:10.1007/s11739-017-1724-7 · Cited by 5
Venous thromboembolism controversies
Adum, J. P. S., Golemi, I., Rios, L. H. P., Quintero, L. A. D., Tafur, A. J., & Caprini, J. A. (2018) · Disease-a-Month · doi:10.1016/j.disamonth.2018.03.003 · Cited by 5
15 years outcomes following bioprosthetic versus mechanical aortic valve replacement in patients aged 50–65 years with isolated aortic stenosis
Rodríguez-Caulo, E. A., Otero-Forero, J., Sánchez-Espín, G., Mataró, M. J., Guzón, A., Porras, C., Villaescusa, J. M., Such, M., & Melero, J. M. (2018) · Cirugía Cardiovascular · doi:10.1016/j.circv.2018.03.002 · Cited by 5
Recent Advances in Thrombosis and Hemostasis—Part VII
Schulman, S. (2021) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0041-1725945 · Cited by 5
Management of Anticoagulation in Patients with Atrial Fibrillation Undergoing PCI: Double or Triple Therapy?
Peterson, B. E., & Bhatt, D. L. (2018) · Current Cardiology Reports · doi:10.1007/s11886-018-1045-0 · Cited by 5
International normalized ratio for the guidance of warfarin treatment in elderly patients after cardiac valve replacement
Ma, Q., & Fang, J. (2018) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2018.7078 · Cited by 5

Authors: Eikelboom, J. W., Connolly, S. J., Brueckmann, M., Granger, C. B., Kappetein, A. P., Mack, M. J., Blatchford, J., Devenny, K., Friedman, J., Guiver, K., Harper, R., Khder, Y., Lobmeyer, M. T., Maas, H., Voigt, J.-U., Simoons, M. L., & Van de Werf, F.
Affiliations: Hamilton Health Sciences (CA)
Boehringer Ingelheim (Germany) (DE)
Duke University (US)
Erasmus MC (NL)
Heart Hospital Baylor Plano (US)
Boehringer Ingelheim (United Kingdom) (GB)
Boehringer Ingelheim (United States) (US)
Boehringer Ingelheim (France) (FR)
KU Leuven (BE)
ORCID: Eikelboom, John W.
Connolly, Stuart J.
Brueckmann, Martina
Granger, Christopher B.
Kappetein, Arie P.
Mack, Michael J.
Blatchford, Jon
Guiver, Kelly
Khder, Yasser
Lobmeyer, Maximilian T.
Voigt, Jens-Uwe
Simoons, Maarten L.
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2013-09-26
Volume: 369
Issue: 13
Pages: 1206-1214
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa1300615
OpenAlex: W2016875529
Cited by: 1,506
References: 27
Citations by year: 2026: 52 · 2025: 84 · 2024: 111 · 2023: 95 · 2022: 102 · 2021: 140 · 2020: 130 · 2019: 113 · 2018: 119 · 2017: 128 · 2016: 116 · 2015: 131 · 2014: 147 · 2013: 36
FWCI: 97.35
Type: journal article
Language: en
Open access: closed
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
Pure Amsterdam UMC (publishedVersion)
EUR Research Repository (Erasmus University Rotterdam) (publishedVersion)
Data Archiving and Networked Services (DANS) (submittedVersion)
EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
VUBIR (Vrije Universiteit Brussel) (submittedVersion)
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Valve Diseases and Treatments
Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
Keywords: dabigatran, warfarin, mechanical heart valves, direct thrombin inhibitors, anticoagulation, thromboembolism, bleeding complications, pericardial bleeding, stroke, aortic valve replacement, mitral valve replacement, dose adjustment
MeSH terms: Dabigatran, Aged, Anticoagulants, Atrial Fibrillation, Benzimidazoles, Female, Heart Valve Prosthesis, Hemorrhage, Humans, Male, Middle Aged, Thromboembolism, Warfarin, beta-Alanine, Stroke

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Dabigatran versus Warfarin in Patients with Mechanical Heart Valves

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks